Zacks Research Forecasts Prothena FY2027 Earnings

Prothena Co. plc (NASDAQ:PRTA) – Zacks Research issued their FY2027 earnings per share estimates for shares of Prothena in a research note issued to investors on Wednesday, March 12th. Zacks Research analyst E. Bagri expects that the biotechnology company will post earnings of ($3.04) per share for the year. The consensus estimate for Prothena’s current full-year earnings is ($4.04) per share.

Prothena (NASDAQ:PRTA) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.06). The firm had revenue of $2.12 million for the quarter, compared to analyst estimates of $7.53 million. Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%.

Other research analysts have also recently issued reports about the stock. StockNews.com raised shares of Prothena from a “sell” rating to a “hold” rating in a report on Monday, February 24th. Piper Sandler increased their target price on Prothena from $94.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. HC Wainwright restated a “buy” rating and issued a $48.00 price target on shares of Prothena in a research note on Friday, February 21st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Prothena in a research report on Friday, February 21st. Finally, Chardan Capital reissued a “buy” rating and issued a $40.00 target price on shares of Prothena in a research report on Friday, February 21st. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $55.00.

Prothena Price Performance

NASDAQ:PRTA opened at $13.74 on Friday. The firm’s fifty day moving average price is $14.40 and its two-hundred day moving average price is $16.14. The company has a market cap of $739.58 million, a P/E ratio of -5.97 and a beta of -0.02. Prothena has a one year low of $11.70 and a one year high of $26.75.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. GSA Capital Partners LLP acquired a new stake in Prothena during the third quarter worth about $484,000. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Prothena by 8.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 122,492 shares of the biotechnology company’s stock worth $2,049,000 after acquiring an additional 9,666 shares in the last quarter. Intech Investment Management LLC bought a new position in Prothena in the third quarter valued at approximately $210,000. Dynamic Technology Lab Private Ltd acquired a new position in Prothena during the third quarter valued at approximately $432,000. Finally, The Manufacturers Life Insurance Company lifted its stake in Prothena by 3.8% during the third quarter. The Manufacturers Life Insurance Company now owns 86,071 shares of the biotechnology company’s stock worth $1,440,000 after purchasing an additional 3,163 shares during the last quarter. Institutional investors own 97.08% of the company’s stock.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.